

PYC THERAPEUTICS Q3 INVESTOR CALL

- **PYC Therapeutics will host an investor meeting/teleconference on Wednesday 27 September, 2023 at 9am AWST (11am AEST) to provide an update to shareholders on progress made through Q2 2023 and the early parts of Q3 2023**
- **The investor update will focus on progress in the ongoing human trials evaluating the safety and efficacy of the first investigational drug candidate to have progressed to clinical trials in a blinding eye disease called Retinitis Pigmentosa type 11 (RP11)**
- **Professor Ian Constable will join PYC's Chief of Research and Development, Sri Mudumba, for the update to discuss progress in the RP11 trial**

PERTH, Australia and SAN FRANCISCO, California – 19 September 2023

PYC Therapeutics CEO Dr. Rohan Hockings will host an investor call on **27 September, 2023 at 9am AWST** (11am AEST, 6pm 26 September USA PST) to provide an update on recent progress made by the Company.

The update will adopt a special format dedicated to the progress of the Company's lead investigational drug candidate known as VP-001 through clinical trials. PYC's Chief of R&D, Sri Mudumba, will facilitate a discussion on this topic with Professor Ian Constable. Prof. Constable is an ophthalmologist and research clinician. He is a pioneer in the field of retinal gene therapy and was the founding managing director and is now patron of the Lions Eye Institute. Prof. Constable is a member of PYC's Scientific Advisory Board and is also a member of the Safety Review Committee for VP-001 in the Platypus clinical study.

Following the discussion on the Company's lead program, PYC's CEO, Rohan Hockings will provide an update on progress in the Company's:

- Second drug development candidate – a first-in-class therapy in another blinding eye disease called Autosomal Dominant Optic Atrophy that is expected to enter human trials next year; and
- Third drug development candidate – a first-in-class therapy for a neurodevelopmental disorder known as Phelan McDermid Syndrome.

The investor call will be held in the McCusker Auditorium, Harry Perkins Institute, 6 Verdun Street, Nedlands, Western Australia for investors who wish to attend in person.

The audio and video link will be available 5 minutes prior to the commencement of the call.

Investors can register for the call via the zoom registration link and submit questions for the Q&A session by emailing info@pyctx.com.

Register in advance for this webinar:

https://us02web.zoom.us/webinar/register/WN_fm5FTif7QLCPEnsuiEA7g

After registering, you will receive a confirmation email containing information about joining the webinar.

About PYC Therapeutics

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorized for release by the CEO of PYC Therapeutics Limited

CONTACT:

info@pyctx.com